CENTRAL TEXAS VETERANS' HEALTHCARE SYSTEM

OLIN E. TEAGUE VETERANS’ MEDICAL CENTER

Download Studies Here What is an R01 Grant?

Recipient of multi-year R01 grant to evaluate efficacy and economic impact.

Lower mean bioburden on EOS^CU than control surface over 30 hours

up to

Fewer healthcare-associated infections

Consecutive years of statistically significant reductions in bioburden and HAIs

What is bioburden?

Bioburden is the number of viable microorganisms that can be found on a surface, in a sample, or in a solution before sterilization.

What are HAIs?

Hospital-associated infections, or healthcare-associated infections, are infections that patients get as a direct result of receiving care in a medical facility.

What is statistical significance?

If results are statistically significant, this means that it is very unlikely that the results are due to chance.

EOS^CU Helps Our Veterans

In June 2016, EOS Surfaces officially entered into a Cooperative Research and Development Agreement (CRADA) with the Central Texas Veterans Health Care System (CTVHCS) in Temple, TX. A CRADA is a legal “contract” that provides an exciting opportunity for NIH researchers to join with partners from private industry and academia in a collective effort to achieve shared research goals. CRADAs aim to promote collaboration across governments, universities, and the private sector to expedite the transfer of innovative, effective, proven, and beneficial technologies to the marketplace. The ongoing study of EOScu under principal investigator Dr. Chetan Jinadatha at the Olin E. Teague VAMC will further test the material’s efficacy in reducing both the bioburden of a patient room and incidents of hospital acquired infection (HAI) while also performing the first known parallel analysis of the positive economic impact of such reductions.

Deploy EOS^CU in Your Facility

friends-fitness-and-man-with-personal-trainer-in-2023-11-27-04-53-24-utc

Preliminary Work: CRADA

The trial was launched in October 2016 at the Olin E. Teague Veterans’ Medical Center (VAMC), part of the Central Texas Veterans’ Healthcare System, located in Temple, Texas.

As one of the largest healthcare systems in the US, the Veterans Health Administration (VHA) provides essential care to more than 8.7 million veterans in 300 VA hospitals, as well as 827 community-based outpatient clinics. Veterans are particularly vulnerable to HAIs and as a result, VA has made infection prevention a top priority. Its Health Services Research & Development Service (HSR&D) has conducted several studies focused on detecting and preventing HAIs.

Phase 1: Publication

The facility outfitted all 120 patient rooms with EOS^CU Preventive|Biocidal Surfaces™ including all countertops, over-the-bed tables and bed rails in the facility. The purpose of the study was to measure the additional protection against bacterial infection above and beyond existing infection control protocols, including reductions in contamination (bioburden) and reductions in HAI rates. The first phase of the study confirmed bioburden reduction while the second phase confirmed statistically significant reductions in HAIs. You can download the studies here.

Phase 2: R01 Application and Approval

The investigative team recognized EOS^CU had potential to become a standard of care, and therefore submitted data from the first study as a part of a R01 application, which was approved. See here for more information.

Phase 3: Ongoing Study

The ongoing study continues to result in data confirming the efficacy of the EOS^CU surface on both HAI rates, bioburden, and economic impact. Even during the COVID-19 pandemic, which occurred while the studies were underway, statistically significant reductions were measures despite the radical changes it experiences. Under the R01 grant, ongoing data collection aims to isolate the specific economic benefits of the infection reductions due to EOS^CU.

Phase 4: The Future

The ongoing research will evaluate potential financial impacts of a biocidal material on a healthcare facility. This type of data will reveal the way EOS^CU can help save lives and money.

2023

IDWeek 2023 Poster Presentation

Demonstrated efficacy against C. difficile spores and infection rates

2022

IDWeek 2022 Poster Presentation

Demonstrated reductions in HAIs and bioburden despite ongoing global pandemic. Poster found here.

2021

COVID-19 Pandemic

Testing continues despite global pandemic, with continued reductions in bioburden and HAIs. Poster found here.

2020

First NIH Study Published

First study demonstrated efficacy against bioburden. Study found here.

2019

NIH R01 Grant Awarded

$3 million NIH grant awarded to study the impact of EOS^CU on bioburden, HAI rates, and hospital costs. EOS^CUfully deployed.

2017

Initial Study Published

Overbed tables only, surveillance and data collection, published here.

2016

Clinical Study Launched

Investigation underway at Central Texas VA.

2015

CRADA

Preliminary work to draft and establish CRADA.

CENTRAL TEXAS VETERANS' HEALTHCARE SYSTEM

Recipient of multi-year R01 grant to evaluate efficacy and economic impact.